From GlobeNewswire: 2025-03-11 08:00:00

Exagen Inc. reported record total revenue of $55.6 million for the full year 2024, with a 62.1% gross margin. They also improved adjusted EBITDA loss by over 40% and commercialized new biomarkers for AVISE CTD. The company aims for positive adjusted EBITDA in the fourth quarter of 2025.

In addition to financial success, Exagen achieved a key milestone of testing 1,000,000 patients with AVISE CTD. They presented innovative research at the 2024 ACR meeting and launched new SLE and RA biomarker assays. Exagen’s CEO is optimistic about the company’s growth and profitability in 2025.

Exagen’s non-GAAP financial measures show improved adjusted EBITDA and reduced operating expenses. Despite challenges, the company remains focused on improving patient care and driving profitability. Interested parties can join a conference call on March 11, 2025, to learn more about the company’s financial results and business update.



Read more at GlobeNewswire:: Exagen Inc. Reports Strong Fourth Quarter and Full-Year